- 2026 年會有漢他病毒疫苗嗎？2¢2%
No hantavirus vaccine is positioned for approval or broad availability by the end of 2026. All active candidates remain in preclinical or very early clinical stages, with no advanced human efficacy trials underway. Recent mRNA platforms, including single-dose candidates tested in hamsters at UTMB and work by Moderna with Korea University, have shown strong protection in rodent models against strains like Andes virus, yet these have not entered Phase 1 human testing. Older DNA vaccine efforts have completed limited Phase 1 safety studies but lack large-scale efficacy data or regulatory advancement. The 2026 cruise-ship outbreak has heightened awareness and prompted some funding discussions, yet development timelines for new vaccines—especially against regionally variable hantaviruses—typically span multiple years absent an extraordinary acceleration program. Realistic shifts before year-end would require unprecedented regulatory fast-tracking or emergency authorization based on preliminary data, scenarios viewed as improbable given current pipelines and resource constraints.
規則
如果任何供人類使用、可使人對漢他病毒產生免疫的疫苗（包括漢他病毒肺症候群（HPS）或腎症候群出血熱（HFRS）疫苗），在市場建立日至 2026年12月31日, 下午11:59 ET 之間獲得美國食品藥物管理局的完整核准，此市場將判定為「是」。否則，此市場將以「否」結算。 此市場判定的主要依據將是 FDA 的官方資訊，包括其核准疫苗清單（https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states）；不過，也可採用可信報導所形成的共識。
機器翻譯。如有爭議，以原文為準。